The DOI matches its Crossref record.
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor
Abstract
Clinical trials of thrombopoietin (TPO), the central regulator of megakaryocytopoiesis, have revealed few side effects associated with its use. We here report a case of pancytopenia associated with the development of neutralizing antibodies to TPO that occurred in a patient who had undergone multicycle chemotherapy with multiple cycles of subcutaneous administration of pegylated recombinant human megakaryocyte growth and development factor. Samples of the patient's bone marrow showed trilineage hypoplasia with absence of myeloid, erythroid, and megakaryocyte progenitor cells but with elevated endogenous levels of erythropoietin, granulocyte colony-stimulating factor, and stem-cell factor. To our knowledge, this is the first report of an aplastic anemia–like syndrome associated with neutralizing antibodies to TPO.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
Bussel, J. B., Kuter, D. J., George, J. N., McMillan, R., Aledort, L. M., Conklin, G. T., Lichtin, A. E., Lyons, R. M., Nieva, J., Wasser, J. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054626 · Cited by 530
Self-citationPEG conjugates in clinical development or use as anticancer agents: An overview
Pasut, G., & Veronese, F. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.02.010 · Cited by 457
Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand
WANG, B., NICHOL, J., & SULLIVAN, J. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.010 · Cited by 295
Self-citationWong, K., Chang, P. Y., Fielden, M., Downey, A. M., Bunin, D., Bakke, J., Gahagen, J., Iyer, L., Doshi, S., Wierzbicki, W., et al. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1625488 · Cited by 57
Metadata
- Authors
- Basser, R. L., O'Flaherty, E., Green, M., Edmonds, M., Nichol, J., Menchaca, D. M., Cohen, B., & Begley, C. G.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-04-01
- Volume
- 99
- Issue
- 7
- Pages
- 2599-2602
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2039211544
- Cited by
- 249
- References
- 0
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. https://app.cochat.ai/papers/10.1182/blood.v99.7.2599
- The paper
- Basser, R. L., O'Flaherty, E., Green, M., Edmonds, M., Nichol, J., Menchaca, D. M., Cohen, B., & Begley, C. G. (2002). Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood. https://doi.org/10.1182/blood.v99.7.2599
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.